HOME ·

Clinical Trial

CSTONE PHARMA-B (02616.HK): IND of CS5007 (EGFR/HER3 bispecific ADC) approved by NMPA, fast-tracked in 23 working days
Tags：
CSTONE PHARMA-B02616.HKClinical Trial
2026-08-21
GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies
Tags：
GENFLEET-B02595.HKClinical Trial
2026-08-20
ABBISKO-B (02256.HK): IND application of oral pan-KRAS inhibitor ABSK211 approved by NMPA
Tags：
ABBISKO-B02256.HKClinical Trial
2026-08-19
HBM HOLDINGS-B (02142.HK): IND application of HBM7004 for advanced solid tumors approved by NMPA
Tags：
HBM HOLDINGS-B02142.HKClinical Trial
2026-08-18
HUTCHMED (00013.HK): ORPATHYS® + TAGRISSO® combination shows statistically and clinically meaningful PFS and OS improvement in MET-driven EGFR-mutated lung cancer
Tags：
HUTCHMED00013.HKClinical Trial
2026-08-17
HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia
Tags：
HANSOH PHARMA03692.HKClinical Trial
2026-08-06
LUYE PHARMA(02186.HK): Innovative Drug LY03015 Completes Bridging Clinical Trial in the US, Pivoting to Efficacy‑focused Clinical Study
Tags：
LUYE PHARMA02186.HKClinical Trial
2026-08-05
LEADS BIOLABS-B(09887.HK): Partner Oblenio Bio Completes First‑in‑Human Phase Ia First‑Patient Dosing of LBL‑051 for Refractory Autoimmune Diseases
Tags：
LEADS BIOLABS-B09887.HKClinical Trial
2026-08-04
HENGRUI PHARMA(01276.HK): SHR‑A2009 for Injection Combined with Adebrelimab Obtains NMPA Clinical Trial Approval for Non‑Small‑Cell Lung Cancer
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-08-04
HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China
Tags：
HAIXI PHARMA02637.HKClinical Trial
2026-08-04
ALPHAMAB-B(09966.HK): CDE Grants Approval for Phase III Clinical Trial of JSKN033 in Cervical Cancer
Tags：
ALPHAMAB-B09966.HKClinical Trial
2026-08-03
CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-03
Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
Tags：
ASCLETIS-B01672.HKClinical Trial
2026-08-03
Henlius (02696.HK): NMPA Approves Clinical Trial Application for HLX43 Combined with Bevacizumab in Solid Tumors
Tags：
HENLIUS02696.HKClinical Trial
2026-07-31
Sirnaomics-B (02257.HK): First Patient Dosed in Phase 2 Clinical Trial of STP705 for Medical Aesthetics
Tags：
SIRNAOMICS-B02257.HKMedical AestheticsClinical Trial
2026-07-30
Henlius (02696.HK): First Patient Dosed in Phase 1 Trial of Trispecific Antibody HLX3902 Targeting STEAP1×CD3×CD28
Tags：
HENLIUS02696.HKClinical Trial
2026-07-30
KEYMED BIO-B (02162.HK): Global Phase III Trial of CMG901 (AZD0901) Meets Primary Endpoint, Delivers Improved OS for 2L+ Gastric Cancer; AstraZeneca Forecasts Peak Sales of USD3-5 Billion
Tags：
KEYMED BIO-B02162.HKAstraZenecaClinical Trial
2026-07-28
LEPU BIO (02157.HK): Global Phase III Trial of CMG901 Meets Primary Endpoint, Significantly Improves Overall Survival of CLDN18.2-positive Advanced Gastric Cancer Patients
Tags：
LEPU BIO02157.HKAstraZenecaClinical Trial
2026-07-28
INNOCARE (09969.HK): Phase III Trial of Fadeucravacitinib (ICP-488) for Moderate to Severe Plaque Psoriasis Meets Primary Endpoint
Tags：
INNOCARE09969.HKClinical Trialprimary endpoint
2026-07-27
SBP GROUP (01177.HK): IM-101 Injection (PreS1 Recombinant Fusion Protein) Obtains NMPA Clinical Trial Approval for Chronic Hepatitis B
Tags：
SBP GROUP01177.HKClinical Trial
2026-07-23
123